Sign in

CIK 0000715446

  • Non-accelerated filer
  • Smaller reporting company

Anixa Biosciences Inc

Sign in to watch
Ticker
ANIX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Oct 31
Incorporated
DE
Entity type
Operating
EIN
112622630
Phone
+1 408-708-9808
Business address
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE, CA, 95118
Former names
ITUS Corp, COPYTELE INC
  1. 4 Open-market buy Chief Executive Officer bought 43,000 shares at $2.23 ($95,890)
  2. 4 Open-market buy President, COO, & CFO bought 9,289 shares at $2.15 ($19,971)
  3. 4 Derivatives Options or other derivatives
  4. 4 Derivatives Options or other derivatives
  5. 4 Derivatives Options or other derivatives
  6. 4 Derivatives Options or other derivatives
  7. 4 Derivatives Options or other derivatives
  8. 4 Option exercise Director acquired 16,000 shares (option exercise)
  9. 4 Open-market buy Director bought 27,226 shares at an average $3.09 ($84,260)
  10. 4 Open-market buy Director bought 8,496 shares at an average $3.01 ($25,568)
  11. 4 Open-market buy Director bought 5,000 shares at $3.09 ($15,450)
  12. 4 Open-market buy Director bought 4,000 shares at $2.68 ($10,720)
  13. 4 Open-market buy Director bought 405 shares at $2.70 ($1,094)
  14. 4 Open-market buy Director bought 7,432 shares at an average $2.66 ($19,749)
  15. 4 Open-market buy Director bought 10,738 shares at $2.52 ($27,060)
  16. 4 Open-market buy President, COO, & CFO bought 6,250 shares at $2.40 ($15,000)
  17. 4 Open-market buy Chief Executive Officer bought 25,000 shares at $2.41 ($60,250)
  18. 4 Grant or award President, COO, & CFO acquired 1,189 shares (grant or award)
  19. 4 Open-market buy Director bought 15,009 shares at $3.28 ($49,230)
  20. 4 Open-market buy Director bought 10,000 shares at $3.63 ($36,300)

Page 3 of 24 · 471 filings